Peregrine Pharmaceuticals has begun evaluating the safety and efficacy of bavituximab in combination with docetaxel in a Phase II trial of patients with advanced breast cancer. Read the rest of this entry »

Biotechnology company Genentech Inc. said Tuesday its cancer drug Avastin succeeded in a breast cancer study, increasing the survival time for patients without having the disease progress. Read the rest of this entry »

Calibrant Biosystems announced a research collaboration with the Yale University School of Medicine to identify novel ovarian and breast cancer drug targets from clinical tissue specimens using Calibrant’s Gemini proteomics platform. Read the rest of this entry »

Peregrine Pharmaceuticals, Inc., a reported that clinical data on its anti-phosphatidylserine (anti-PS) monoclonal antibody bavituximab was discussed at the 10th Annual International Symposium on Anti-Angiogenic Agents (Angio 2008) in La Jolla, CA. Read the rest of this entry »

Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) today announced the completion of its IoGen(TM) Phase III pivotal trial. Read the rest of this entry »

Japanese drugmaker Eisai and its U.S. subsidiary have changed the schedule for submitting a new drug application (NDA) to the FDA for E7389 for third-line treatment of advanced breast cancer patients who were pretreated with anthracycline, taxane and capecitabine. Read the rest of this entry »

Pharmaceutical firm GlaxoSmithKline (GSK) will introduce to the local market today a cancer treatment drug that slows down the progression of breast cancer. Read the rest of this entry »

Researchers at the Tenovus Centre for Cancer Research at Cardiff University have made a breakthrough in breast cancer treatment that could help save the lives of women who become resistant to breast cancer drugs such as tamoxifen. Read the rest of this entry »

Researchers involved in a multi-center trial have reported that adding ixabepilone (Ixempra™) to Xeloda® (capecitabine) improves outcomes of patients with ER/PR/HER2-negative metastatic breast cancer (MBC) resistant to anthracyclines and taxanes. Read the rest of this entry »

Researchers affiliated with the ATLAS (Adjuvant Tamoxifen, Longer against Shorter) study have reported that continuation of tamoxifen beyond 5 years reduces recurrences over the next few years Read the rest of this entry »

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) and Eisai’s U.S. subsidiary, Eisai Corporation of North America (Headquarters: New Jersey, the United States, Chairman & CEO: Hajime Shimizu), today announced a change in the schedule for submission to the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) for E7389 (generic name: eribulin mesylate) for third-line treatment of advanced breast cancer in patients who were pretreated with anthracycline, taxane and capecitabine. Read the rest of this entry »

A NORTH woman has joined forces with a fellow breast cancer patient to mount a legal challenge to an NHS decision to prevent them both having life prolonging drugs. Read the rest of this entry »

Swiss pharmaceutical giant Roche reported Wednesday a better-than-expected 2007 net profit of 11.4 billion Swiss francs (10.4 billion dollars, 7.1 billion euros), boosted by cancer drug sales. Read the rest of this entry »

Researchers involved in an international study have reported that the combination of Omnitarg and Herceptin has significant activity in women with HER2-positive breast cancer who progressed on Herceptin alone. Read the rest of this entry »

Patients who received panitumumab (Vectibix) plus FOLFOX or FOLFIRI had a faster progression of metastatic colorectal cancer and were more likely to experience severe toxicities. Read the rest of this entry »

German drugmaker Wilex will conduct a Phase II trial with WX-671 in combination with the chemotherapeutic agent Xeloda in patients with HER2-receptor negative metastatic breast cancer. Read the rest of this entry »

IPSOGEN SAS has announced the signature of a license agreement with Universite Libre de Bruxelles (ULB), Belgium for the worldwide and exclusive rights on the Genomic Grade™.
Read the rest of this entry »

 The Munich-based biopharmaceutical company Wilex AG (ISIN DE0006614720 / Frankfurt Stock Exchange / Prime Standard) today announced that the U.S. Food and Drug Administration (FDA) approved an Investigational New Drug application (IND) for a clinical Phase II trial with its drug candidate WX-671.

Read the rest of this entry »

Report Buyer, the online destination for business intelligence for major industry sectors, has added a report which finds that an FDA advisory panel has said that Genentech/Roche’s Avastin® should not receive FDA approval for metastatic breast cancer.
Read the rest of this entry »